hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:13:27 - browse：67

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

explore

WSS

Kidney transplant patients stopped immunosuppressants in trial

Health AI: on the border between health care and tech

Biogen’s boardroom scandal saddles CEO with first crisis

Aspartame and sugar

Mark Cuban is blaming the wrong people for high drug costs

Judge sides with young activists in first

knowledge

hotspot

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to know about the judge who will handle the Trump case

Heart attack and stroke risk calculators need revising

Dozens dead from Maui wildfires: What we know about the victims

As demand for Covid shots wanes, Moderna seeks its next success

Be careful with at

Psychedelics group wrestles with new pharma identity

Indictment alleges Trump's ex

The high cost of giving birth even with insurance

Illinois Supreme Court finds assault weapons ban constitutional

leisure time

Patients, digital health players weigh in on FTC's data privacy plan

Dozens dead from Maui wildfires: What we know about the victims

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Travis Kelce and the trap of celebrity vaccine endorsements

Judge sides with young activists in first

Humans aren't the only ones with an imagination. Rats have it too

explore

explore

Wikipedia

entertainment